Metformin drug formulations
Pro Research Analysisby 
Searched over 200M research papers
Metformin Drug Formulations: Types and Key Characteristics
Metformin, a widely used antidiabetic medication, is available in several formulations designed to optimize its efficacy, minimize side effects, and improve patient compliance. The main types include immediate-release (IR), extended-release (XR), delayed-release (DR), and various advanced delivery systems such as microspheres, nanoparticles, transdermal gels, and inhaled powders.
Immediate-Release, Extended-Release, and Delayed-Release Metformin
Studies show that immediate-release (met-IR), extended-release (met-XR), and delayed-release (met-DR) formulations of metformin are equally effective in controlling blood glucose levels, as measured by fasting plasma glucose and HbA1c changes. However, met-XR may offer additional benefits, such as a non-significant trend toward weight reduction and a significant decrease in LDL cholesterol compared to met-IR. Notably, met-DR is associated with a marked reduction in gastrointestinal side effects, which can improve patient adherence to therapy .
Extended-Release Oral Suspensions
Extended-release oral suspensions of metformin have been developed to facilitate easier swallowing, especially for patients who have difficulty with tablets. These suspensions use coated pellets to achieve sustained drug release, with optimized formulations capable of releasing over 85% of the drug within 8 hours, following zero-order kinetics for consistent plasma levels .
Microspheres, Nanoparticles, and Advanced Oral Delivery
Microparticulate and nanoparticulate systems, including mucoadhesive microspheres and nanoparticles, have been formulated to enhance metformin’s bioavailability and provide sustained drug release. These systems can reduce dosing frequency, minimize gastrointestinal side effects, and potentially improve the drug’s anticancer effects. Studies indicate that such formulations can achieve controlled drug release, improved intestinal absorption, and enhanced hypoglycemic and anticancer activity in experimental models Kotha2023Çetin2016. Additionally, encapsulating metformin in calcium alginate beads with niosomes or chitosomes further sustains drug release in the intestine and enhances the hypoglycemic effect, which may allow for lower dosing and fewer side effects .
Transdermal and Topical Formulations
To address gastrointestinal intolerance, transdermal formulations of metformin have been developed using liquid crystalline lipid particles (LCLP) and gels. These topical systems provide sustained drug release, high skin retention, and significant blood glucose reduction in diabetic animal models, without causing skin irritation or damage . Similarly, metformin-loaded ethosomes and hyaluronic acid-coated chitosan/gelatin nanoparticles have been designed for topical application, particularly for skin cancer and melanoma. These nanoformulations enhance skin penetration, provide sustained drug release, and demonstrate superior anticancer activity compared to free metformin Ebrahimnejad2023Mousa2022.
Injectable and Inhaled Metformin Formulations
Injectable slow-release metformin formulations, such as thermoresponsive gels, have been developed for localized drug delivery, especially in cancer therapy. These formulations allow high local drug concentrations near tumors, resulting in significant antiproliferative effects in animal models . Inhaled dry powder formulations combining metformin with other drugs (e.g., moxifloxacin) are being explored for pulmonary delivery, such as in the treatment of tuberculosis, offering good lung retention and cell tolerability .
Conclusion
Metformin is available in a variety of formulations tailored to different therapeutic needs. While traditional IR, XR, and DR tablets remain effective for glycemic control, advanced delivery systems—such as oral suspensions, microspheres, nanoparticles, transdermal gels, and inhaled powders—offer improved bioavailability, reduced side effects, and expanded therapeutic applications, including cancer and infectious diseases. These innovations aim to enhance patient compliance and broaden the clinical utility of metformin Tarry-Adkins2021Patil2024Kotha2023+7 MORE.
Sources and full results
Most relevant research papers on this topic